Clinical Practice Guidelines for the management of locally advanced ...

More documents

Recommendations

Info

2. National Health and Research Council. How to review the evidence: Systematic identification and review of scientific literature. Commonwealth of Australia, 1999. Available at
APPENDIX 2 WORKING PARTY MEMBERS AND CONTRIBUTORS Management of Metastatic Prostate Cancer Guidelines Working Party Membership Professor Villis Marshall AC (Chair) Urologist – Royal Adelaide Hospital Adelaide SA Mr Don Baumber Consumer – Gold Coast QLD Professor Damian Bolton Urologist – Melbourne VIC A/Professor Mark Boughey Palliative care specialist – Melbourne VIC Dr Mary Brooksbank AM Palliative care physician – Adelaide SA Professor Suzanne Chambers General Manager Research, Cancer Council Queensland, Brisbane QLD Ms Helen Crowe Urological Nurse – Victorian Urological Nurses Society, Melbourne VIC Professor David Currow* Palliative care physician – Adelaide SA Ms Melissa Dougherty* Epidemiologist – Adelaide SA Dr Joshua Dass Radiation oncologist – Townsville QLD Professor Gillian Duchesne** Radiation oncologist – Melbourne VIC Professor RA ‘Frank’ Gardiner AM Urologist – Royal Brisbane and Women’s Hospital, Brisbane QLD Dr Kumar Gogna Radiation oncologist – Mater Centre, Brisbane QLD Dr Howard Gurney Medical oncologist – Westmead Hospital, Sydney NSW Professor David Handelsman Endocrinologist – ANZAC Research Institute, Sydney NSW Mr Trevor Hunt Consumer – Adelaide SA (deceased 22 June 2009) Dr Andrew Kneebone Radiation oncologist – Royal North Shore Hospital, Sydney NSW Mr Bill McHugh Consumer – Brisbane QLD Ms Jill Margo Medical journalist – Sydney NSW A/Professor Jeremy Millar*** Radiation oncologist – Alfred Hospital, Melbourne VIC Professor Dianne O’Connell Epidemiologist – Cancer Council NSW, Sydney NSW Professor Ian Olver Medical oncologist – Cancer Council Australia, Sydney NSW Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer 124
Page 1:
Clinical Practice Guidelines for th
Page 4 and 5:
4 Biochemical relapse .............
Page 6 and 7:
FOREWORD The management of prostate
Page 8 and 9:
SUMMARY OF CLINICAL PRACTICE RECOMM
Page 10 and 11:
SUMMARY OF RECOMMENDATIONS Chapter
Page 12 and 13:
Chapter Recommendations Grade Refs
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
1 INTRODUCTION 1.1 Natural history
Page 22 and 23:
2 PSYCHOSOCIAL CARE The diagnosis a
Page 24 and 25:
2.2 Effect of psychological and cog
Page 26 and 27:
Evidence summary Level References T
Page 28 and 29:
Recommendation Men with advanced pr
Page 30 and 31:
An Australian cross-sectional study
Page 32 and 33:
10. Dunn J, et al. A review of peer
Page 34 and 35:
41. Sharpley CF, Christie DRH. An a
Page 36 and 37:
different treatments from different
Page 38 and 39:
Evidence summary Level References I
Page 40 and 41:
Evidence summary Level References F
Page 42 and 43:
Despite these reservations and the
Page 44 and 45:
For non-metastatic disease there we
Page 46 and 47:
Evidence summary Level References T
Page 48 and 49:
monotherapy for low-to-intermediate
Page 50 and 51:
Evidence summary Level References M
Page 52 and 53:
for surgery, suggesting that surger
Page 54 and 55:
Microscopic fully resected node pos
Page 56 and 57:
All three trials demonstrated impro
Page 58 and 59:
Evidence summary Level References B
Page 60 and 61:
of an international multicentre ran
Page 62 and 63:
45. Melton LJ, III, Alothman KI, Kh
Page 64 and 65:
76. Little DJ, Kuban DA, Levy LB, Z
Page 66 and 67:
105. Thompson IM, Tangen CM, Parade
Page 68 and 69:
4.2 Androgen deprivation therapy (e
Page 70 and 71:
Evidence summary Level References F
Page 72 and 73:
therapy since such studies would be
Page 74 and 75:
apparent in trials comparing CAB wi
Page 76 and 77:
QLQ instrument published by Cleary
Page 78 and 79:
Note: Larger well-powered studies h
Page 80 and 81:
Eight trials examined acute toxicit
Page 82 and 83:
half of patients experienced pain r
Page 84 and 85:
olus) in addition to radiotherapy a
Page 86 and 87:
References 1. Seidenfeld J, Samson
Page 88 and 89:
Cooperative Group. Scandinavian Jou
Page 90 and 91:
Oncology Group, TROG 96.05). Radiot
Page 92 and 93: trial. European Journal of Cancer 1
Page 94 and 95: 6 CASTRATION-RESISTANT PROSTATE CAN
Page 96 and 97: the median overall survival for pat
Page 98 and 99: There are two points regarding bisp
Page 100 and 101: with bone pain at study entry. At n
Page 102 and 103: Recently, there have been reports o
Page 104 and 105: of these studies 56, 58 and in the
Page 106 and 107: Side effects (toxicity) As these ra
Page 108 and 109: hydrocortisone respectively. Tannoc
Page 110 and 111: 5. Manikandan R, Srirangam SJ, Pear
Page 112 and 113: 33. Elomaa I, Kylmala T, Tammela T
Page 114 and 115: 60. Janknegt RA, Abbou CC, Bartolet
Page 116 and 117: physiotherapists, occupational ther
Page 118 and 119: 7.5 Q2: Symptom control There was e
Page 120 and 121: Informal or family caregivers deriv
Page 122 and 123: 8. Hughes SL, Weaver FM, Giobbie-Hu
Page 124 and 125: 8 COMPLEMENTARY AND ALTERNATIVE (UN
Page 126 and 127: corresponding benefit in obstructiv
Page 128 and 129: 3. Eisenberg DM, Kessler RC, Van Ro
Page 130 and 131: areas of the state were more likely
Page 132 and 133: 8 Miller DC, Litwin MS, Bergman J,
Page 134 and 135: 10 EMERGING THERAPIES It is impossi
Page 136 and 137: APPENDIX 1 GUIDELINE DEVELOPMENT PR
Page 138 and 139: study type. Studies published befor
Page 140 and 141: Grade of recommendation Description
Page 144 and 145: Dr Carole Pinnock AM Principal rese
Page 146 and 147: Surgery Professor Villis Marshall A
Page 148 and 149: APPENDIX 3 TNM CLASSIFICATION OF PR
Page 150 and 151: Summary Prostate T1 T2 T3 T4 N1 M1a
Page 152 and 153: APPENDIX 4 ABBREVIATIONS AND GLOSSA
Page 154 and 155: Glossary Actuarial survival A metho
Page 156 and 157: Effectiveness The extent to which a
Page 158 and 159: Lymph nodes Small, generally pea-si
Page 160 and 161: Each stage is divided into subgroup
Page 162 and 163: APPENDIX 6 - ORGANISATIONS WHICH PR
Page 164 and 165: Consultant Urologist, Royal Brisban
Page 166 and 167: No conflict of interest to declare.
Page 168 and 169: Index to Clinical practice guidelin
Page 170 and 171: cardiovascular mortality 19, 54, 55
Page 172 and 173: androgen deprivation therapy (ADT)
Page 174 and 175: and surgery 32-34 survival 18 toxic
Page 176 and 177: and chemotherapy 89-90 see also bon
Page 178 and 179: spinal cord compression 62-63 see a
Page 180 and 181: systemic 141 Tasmania Association f
show all

Clinical Practice Guidelines for the management of locally advanced ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?